MARKET NEWS AND UPDATES.
Get notified for Latest News and Market Alerts.
Get notified for Latest News and Market Alerts.
×
CMP as on 12-Aug-22 15:57
₹ 682.85Open
₹ 693.45Turnover (lac)
₹ 5,133Prev. Close
₹ 690.25Day's Vol (shares)
₹ 7,51,684CMP as on12-Aug-22 15:29
₹ 682.25Open
₹ 695.00Turnover (lac)
₹ 494Prev. Close
₹ 689.90Day's Vol (shares)
₹ 25,660CMP as on 12-Aug-22 0:00
₹ 684.15Open
₹ 696.05Open Interest(Contracts)
₹ 92,44,600VWAP
₹ 687.88Day's Vol (shares)
₹ 22,38,900Lupin receives USFDA approval for Meclizine Hydrochloride Tablets
Lupin reported a net loss of Rs 89.1 crore in Q1 FY23 as against a net profit of Rs 542.5 crore in Q1 FY22.
Nilesh Gupta, Managing Director, Lupin Limited, commented on the results, saying, "Our numbers are muted this quarter, but we expect a
Sales decline 14.95% to Rs 3603.96 crore
In the United States, Azilsartan Medoxomil Tablets (RLD Edarbi) had an estimated annual sale of USD 101 million as per IQVIA MAT March
The drug major on Monday (25 July 2022) announced that it received approval from the US drug regulator for Azilsartan Medoxomil tablets
Lupin allots 16,772 equity shares under ESOP
Lupin grants 12,745 stock options
On 3 August 2022
Lupin Diagnostics will provide accurate diagnoses to doctors throughout the patient journey by leveraging innovative technologies for e
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity
